Drug Search Results
More Filters [+]

AVX-001

Alternative Names: avx-001, avx001, avx 001, akh-217, akh217, akh 217
Latest Update: 2024-04-01
Latest Update Note: PubMed Publication

Product Description

topical cytosolic phospholipase A2 inhibitor

Mechanisms of Action: Immunomodulator,PLA2 Modulator,TNF Inhibitor

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Topical

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Avexxin AS
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for AVX-001

Countries in Clinic:

Active Clinical Trial Count: 1

Highest Development Phases

Phase 2: Keratosis, Actinic

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

COAKs

P2

Completed

Keratosis, Actinic

2022-03-11

Recent News Events